DISCO Pharmaceuticals is a biopharmaceutical company focused on redefining cancer drug discovery by developing novel cancer-selective cell surface targets for the creation of innovative therapeutics.

DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.

DISCO Pharmaceuticals GmbH

Meet us at the DISCO!

The DISCO Pharmaceuticals GmbH website that is. Meet the team and read more about what we do and how we will transform the landscape of cancer care.

www.discopharma.de

Keep up to date with what's happening at DISCO by following us at DISCO Pharmaceuticals GmbH on LinkedIn and @DISCOPharma on #X

#surfaceome #proteomics #optoproteomics #drugdiscovery #biotech

Introducing DISCO Pharmaceuticals GmbH! The surfaceome company. 

Translating over a decade of research, DISCO launches today with its revolutionary surface proteomics platform to identify novel cancer targets on the cell surface at scale, and to develop first in class drugs. 

DISCO's mission is to improve treatment options for patients living with cancer by unleashing the full potential of targeted cancer therapies.  

Find out more: https://bit.ly/48qI8Fz

#surfaceome #proteomics #optoproteomics #drugdiscovery #biotech

DE:DISCOPHARMA

DISCO Pharmaceuticals

Analysis Not Available